Ticagre%252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252528ticagrelor%252525252525252525252525252525252525252525252525252525252529

# Ticagrelor ## Overview Ticagrelor is an oral, direct-acting, reversibly binding P2Y$_{12}$ platelet inhibitor. ## Primary Indications * Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). * Prevention of stent thrombosis in patients treated with a drug-eluting stent. ## Adult Dosing * **ACS:** Loading dose of 180 mg once daily for the first dose, followed by 90 mg twice daily. * **History of MI (at least 1 year post-ACS/MI):** 60 mg once daily. * **Stent Thrombosis:** Dosing typically follows ACS guidelines or local protocol, often 180 mg loading dose then 90 mg twice daily, with duration guided by clinical assessment and risk. ## Pediatric Dosing Ticagrelor is not approved for use in pediatric patients. Safety and efficacy have not been established. ## Dose Adjustments * **Hepatic Impairment:** No dose adjustment is needed in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment. * **Renal Impairment:** No dose adjustment is needed in mild to moderate renal impairment. Use with caution in severe renal impairment. * **Concomitant CYP3A4 Inhibitors/Inducers:** Caution and potential dose reduction (to 60 mg twice daily) may be considered with potent CYP3A4 inhibitors or in patients with increased exposure. Avoid potent CYP3A4 inducers. ## Contraindications * Active pathological bleeding. * History of transient ischemic attack (TIA) or stroke. * Known hypersensitivity to ticagrelor or any component of the formulation. ## Adverse Effects * **Most Common:** Dyspnea, bradycardia, bleeding (including life-threatening and fatal). * **Serious:** Major bleeding, intracranial hemorrhage, ventricular pauses, profound bradycardia. ## Key Drug Interactions * **CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4; coadministration with substrates of this enzyme (e.g., simvastatin, atorvastatin, certain calcium channel blockers) can increase their plasma concentrations and risk of toxicity. Consider lower doses of the CYP3A4 substrate. * **CYP3A4 Inducers:** Potent inducers (e.g., rifampin, phenytoin, carbamazepine) can decrease ticagrelor exposure and efficacy. * **CYP3A4 Inhibitors:** Potent inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase ticagrelor exposure and risk of bleeding. * **Aspirin (ASA):** Avoid chronic use of $>100$ mg ASA with ticagrelor 90 mg twice daily, as it may increase bleeding risk without added benefit. Continue ASA for ACS indication. Duration of dual antiplatelet therapy (DAPT) with ASA should be individualized. * **Other Antithrombotics:** Concomitant use with other anticoagulants or antiplatelet agents increases bleeding risk. ## Monitoring * **Bleeding:** Monitor for signs and symptoms of bleeding, especially during the initial months of therapy. * **Heart Rate:** Ticagrelor can cause bradycardia; monitor heart rate, particularly in patients with pre-existing risk factors. * **Renal and Hepatic Function:** Baseline and periodic monitoring may be appropriate, especially in patients with pre-existing impairment. ## Clinical Pearls * Ticagrelor is a P2Y$_{12}$ inhibitor and should be used in conjunction with aspirin unless contraindicated. * The 90 mg twice daily dose is typically for ACS patients, while the 60 mg once daily dose is for long-term maintenance after ACS/MI. * Dyspnea is a common side effect and is generally not related to underlying cardiac or pulmonary disease. It usually resolves with continued treatment or dose reduction. * Discontinuation of ticagrelor can increase the risk of thrombotic events, especially in patients with ACS or drug-eluting stents. Reassess the risk/benefit of continuing therapy if discontinuation is considered. * Dosing for ticagrelor should be confirmed with current prescribing information and local protocols, especially regarding duration of dual antiplatelet therapy and use in specific patient populations. --- *Disclaimer: This information is intended for healthcare professionals. Always consult the official product prescribing information and relevant clinical guidelines for complete and up-to-date information.*